Mário Raimundo

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Increased Fluid Administration After Early Acute Kidney Injury is Associated with Less Renal Recovery

Mário Raimundo, Siobhan Crichton, John R. Martin et al. · Shock · 2015 · 70 citations · Full text

Low Systemic Oxygen Delivery and BP and Risk of Progression of Early AKI

Mário Raimundo, Siobhan Crichton, Yadullah Syed et al. · Clinical Journal of the American Society of Nephrology · 2015 · 58 citations · Full text

Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease: A Dynamic and Life-Threatening Triad

Mário Raimundo, José António Lopes · Cardiology Research and Practice · 2011 · 49 citations · Full text

Hypertension, Metabolic Disorder, Obesity +17